Ayala Pharmaceuticals (NASDAQ:ADXS) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a research report report published on Monday morning. The brokerage issued a sell rating on the stock.

Ayala Pharmaceuticals Stock Down 74.3 %

Shares of ADXS stock opened at $0.03 on Monday. Ayala Pharmaceuticals has a 12 month low of $0.00 and a 12 month high of $1.49. The company has a market cap of $1.15 million, a PE ratio of 0.00 and a beta of 1.81. The business’s 50 day moving average is $0.05 and its two-hundred day moving average is $0.12.

Ayala Pharmaceuticals Company Profile

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.